Ascendis Pharma A (ASND) Return on Capital Employed (2015 - 2026)
Ascendis Pharma A (ASND) posted Return on Capital Employed of 1.07% for Q1 2026, up 98.62% sequentially from 77.11% in Q4 2025, and down 3128135.0% YoY from N/an in Q1 2025.
Ascendis Pharma A (ASND) Return on Capital Employed (2015 - 2026) Analysis & Trends
Ascendis Pharma A has reported Return on Capital Employed for 12 years, with the latest figure at 1.07% in Q1 2026.
- Quarterly Return on Capital Employed fell 3128135.0% year-over-year to 1.07% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.07% (down 3128135.0% YoY) and the FY2025 annual result came in at 13.29%, up 899.0% from the prior year.
- Return on Capital Employed climbed to 1.07% in Q1 2026 per ASND's latest filing, from 77.11% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 353792.71% in Q2 2025 and troughed at 3250.34% in Q1 2024.
- A 5-year average of 41538.82% and a median of 47.24% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed soared 35323588 bps in 2025, then tumbled 3128135 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 57.78% in 2022, then plunged by 572 bps to 388.46% in 2023, then surged by 7159 bps to 27420.7% in 2024, then plunged by 100 bps to 77.11% in 2025, then surged by 99 bps to 1.07% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 1.07%, 77.11%, and 297625.78% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -1.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.07% |
| Dec 31, 2025 | -77.11% |
| Sep 30, 2025 | 297,625.78% |
| Jun 30, 2025 | 353,792.71% |
| Mar 31, 2025 | 31,280.29% |
| Dec 31, 2024 | 27,420.70% |
| Sep 30, 2024 | -388.80% |
| Jun 30, 2024 | 556.83% |
| Mar 31, 2024 | -3,250.34% |
| Dec 31, 2023 | -388.46% |
| Sep 30, 2023 | -87.29% |
| Jun 30, 2023 | -79.67% |
| Mar 31, 2023 | -69.84% |
| Dec 31, 2022 | -57.78% |
| Sep 30, 2022 | -47.24% |
| Jun 30, 2022 | -39.63% |
| Mar 31, 2022 | -29.22% |
| Dec 31, 2021 | -30.52% |
| Sep 30, 2021 | -47.89% |
| Jun 30, 2021 | -49.30% |